Page last updated: 2024-08-23

lirinidine and Diffuse Mixed Small and Large Cell Lymphoma

lirinidine has been researched along with Diffuse Mixed Small and Large Cell Lymphoma in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	1 (100.00)	2.80

Authors

Authors	Studies
Ansell, SM; Armand, P; Borrello, I; Gutierrez, M; Lesokhin, A; Popa McKiver, M; Timmerman, J; Zhu, L	1

Trials

1 trial(s) available for lirinidine and Diffuse Mixed Small and Large Cell Lymphoma

Article	Year
A phase 1b study of dual PD-1 and CTLA-4 or KIR blockade in patients with relapsed/refractory lymphoid malignancies. Leukemia, 2021, Volume: 35, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Alkaloids; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CTLA-4 Antigen; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Hodgkin Disease; Humans; Ipilimumab; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Nivolumab; Prognosis; Programmed Cell Death 1 Receptor; Receptors, KIR; Salvage Therapy; Survival Rate; Young Adult	2021

Article

Year

A phase 1b study of dual PD-1 and CTLA-4 or KIR blockade in patients with relapsed/refractory lymphoid malignancies.

Leukemia, 2021, Volume: 35, Issue:3

Topics: Adult; Aged; Aged, 80 and over; Alkaloids; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CTLA-4 Antigen; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Hodgkin Disease; Humans; Ipilimumab; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Nivolumab; Prognosis; Programmed Cell Death 1 Receptor; Receptors, KIR; Salvage Therapy; Survival Rate; Young Adult

2021